Jucinac 600mg Tablet contains Acetylcysteine 600mg, a mucolytic agent used primarily to reduce the viscosity of mucus in respiratory conditions characterized by excessive or thickened secretions. Acetylcysteine acts by breaking disulfide bonds in mucoproteins, thereby decreasing mucus thickness and facilitating expectoration. It is commonly indicated for the management of chronic obstructive pulmonary disease (COPD), bronchitis, cystic fibrosis, and other respiratory disorders where mucus clearance is impaired. Additionally, Acetylcysteine serves as an antidote in the treatment of acetaminophen (paracetamol) overdose by replenishing intracellular glutathione stores, thereby preventing hepatic injury. Jucinac 600mg is administered orally, with dosage and duration tailored according to the specific clinical condition and patient response. The medication is generally well tolerated; however, adverse effects may include gastrointestinal disturbances such as nausea, vomiting, and rarely, hypersensitivity reactions. Caution is advised in patients with asthma or bronchospasm due to the potential for bronchial irritation. Jucinac should be used under medical supervision, especially in individuals with pre-existing liver or kidney impairment. Proper hydration is recommended to enhance mucolytic efficacy. This formulation offers a convenient dosage strength to optimize therapeutic outcomes in patients requiring mucolytic therapy or acetaminophen toxicity management.